Telmisartan Tab Hypertension

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension

Treatments: Drug: Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)

Study type: Observational

Funder types: Industry

Identifiers

NCT00890084

502.581

Details and patient eligibility

About

To assess the efficacy of telmisartan in hypertensive patients with high cardiovascular risk

Full description

Study Design:

Enrollment: 2,913 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Hypertensive patients with BP. 140/90mmHgand high and very high cardiovascular risk according to the ESH/ESC Guidelines 2007 and in whom the prescriber has taken the decision to start treatment with telmisartan 40 or 80 mg, with or without HCTZ 12.5 mg or 25 mg, in the usual way and in line with the SmPC and reimbursement criteria

Exclusion criteria

Contra-indications as in the Summary of Product Characteristics

Trial design

2,913 participants in 1 patient group

Group1

Treatment:

Drug: Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)